Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Laurie Gaspar to Radiotherapy, Intensity-Modulated

This is a "connection" page, showing publications Laurie Gaspar has written about Radiotherapy, Intensity-Modulated.

 
Connection Strength
 
 
 
1.252
 
  1. Ding M, Newman F, Chen C, Stuhr K, Gaspar LE. Dosimetric comparison between 3DCRT and IMRT using different multileaf collimators in the treatment of brain tumors. Med Dosim. 2009; 34(1):1-8.
    View in: PubMed
    Score: 0.293
  2. Gaspar LE, Ding M. A review of intensity-modulated radiation therapy. Curr Oncol Rep. 2008 Jul; 10(4):294-9.
    View in: PubMed
    Score: 0.283
  3. Vinogradskiy Y, Rusthoven CG, Schubert L, Jones B, Faught A, Castillo R, Castillo E, Gaspar LE, Kwak J, Waxweiler T, Dougherty M, Gao D, Stevens C, Miften M, Kavanagh B, Guerrero T, Grills I. Interim Analysis of a Two-Institution, Prospective Clinical Trial of 4DCT-Ventilation-based Functional Avoidance Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018 11 15; 102(4):1357-1365.
    View in: PubMed
    Score: 0.144
  4. Carlson JA, Reddy K, Gaspar LE, Ney D, Kavanagh BD, Damek D, Lillehei K, Chen C. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials. J Neurooncol. 2015 Jun; 123(2):251-7.
    View in: PubMed
    Score: 0.113
  5. Ney DE, Carlson JA, Damek DM, Gaspar LE, Kavanagh BD, Kleinschmidt-DeMasters BK, Waziri AE, Lillehei KO, Reddy K, Chen C. Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma. J Neurooncol. 2015 Mar; 122(1):135-43.
    View in: PubMed
    Score: 0.111
  6. Reddy K, Gaspar LE, Kavanagh BD, Chen C. Hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy may alter the patterns of failure in patients with glioblastoma multiforme. J Med Imaging Radiat Oncol. 2014 Dec; 58(6):714-21.
    View in: PubMed
    Score: 0.107
  7. Reddy K, Gaspar LE, Kavanagh BD, Waziri A, Damek DM, Ney D, Lillehei KO, Chen C. Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide. J Neurooncol. 2013 Aug; 114(1):111-6.
    View in: PubMed
    Score: 0.099
  8. Chen C, Damek D, Gaspar LE, Waziri A, Lillehei K, Kleinschmidt-DeMasters BK, Robischon M, Stuhr K, Rusthoven KE, Kavanagh BD. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):1066-74.
    View in: PubMed
    Score: 0.083
  9. Potters L, Gaspar LE, Kavanagh B, Galvin JM, Hartford AC, Hevezi JM, Kupelian PA, Mohiden N, Samuels MA, Timmerman R, Tripuraneni P, Vlachaki MT, Xing L, Rosenthal SA. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guidelines for image-guided radiation therapy (IGRT). Int J Radiat Oncol Biol Phys. 2010 Feb 01; 76(2):319-25.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)